Intellectual property and the valuation of biotechnology
The role of intellectual property (IP) as an important value determinant is widely recognized. This article tries to quantify the role of IP in companies valuation by comparing a sample of biotechnology companies (46 companies included in the Genetic Engineering News Index:GEN-Dex) to the companies included in the Dow Jones Index. Conventional wisdom suggests that the biotechnology sector derives more significant portion of its value from IP. The article proposes a new measure for the significance of IP in the determination of value, which is named the IP Intensity (IPI). Comparison of the distribution of IPI in the two samples demonstrates that this measure is a useful tool for the analysis of value determination.
When requesting a correction, please mention this item's handle: RePEc:wpa:wuwpfi:9709002. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (EconWPA)
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If references are entirely missing, you can add them using this form.
If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.
Please note that corrections may take a couple of weeks to filter through the various RePEc services.